Although anti-PD-1 antibodies have shown significant effects in the treatment of various cancers, their efficacy in BC remains limited, primarily due to the complexity of the BC immune microenvironment and the heterogeneous PD-L1 expression by tumor cells 51, 100, 101. This evidence concerns the gene CD274 and breast cancer.